Show simple item record

dc.contributor.authorMagnussen, Synnøveen_US
dc.contributor.authorHadler-Olsen, Elin Synnøveen_US
dc.contributor.authorCostea, Daniela Elenaen_US
dc.contributor.authorBerg, Elien_US
dc.contributor.authorCavalcanti Jacobsen, Cristiane de Albuquerqueen_US
dc.contributor.authorMortensen, Benteen_US
dc.contributor.authorSalo, Tuulaen_US
dc.contributor.authorMartinez, Inigo Zubiavrreen_US
dc.contributor.authorWinberg, Jan-Olofen_US
dc.contributor.authorUhlin-Hansen, Larsen_US
dc.contributor.authorSvineng, Gunbjørgen_US
dc.date.accessioned2017-12-18T13:09:55Z
dc.date.available2017-12-18T13:09:55Z
dc.date.issued2017-05-19
dc.PublishedMagnussen S, Hadler-Olsen ES, Costea DE, Berg E, Cavalcanti Jacobsen CDAC, Mortensen b, Salo T, Martinez IZ, Winberg J-O, Uhlin-Hansen L, Svineng g. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: Regulation by transforming growth factor - beta1 (TGF-beta1) and potential effects on migration and invasion. BMC Cancer. 2017;17:350eng
dc.identifier.issn1471-2407
dc.identifier.urihttps://hdl.handle.net/1956/17013
dc.description.abstractBackground: Urokinase plasminogen activator (uPA) receptor (uPAR) is up-regulated at the invasive tumour front of human oral squamous cell carcinoma (OSCC), indicating a role for uPAR in tumour progression. We previously observed elevated expression of uPAR at the tumour-stroma interface in a mouse model for OSCC, which was associated with increased proteolytic activity. The tumour microenvironment regulated uPAR expression, as well as its glycosylation and cleavage. Both full-length- and cleaved uPAR (uPAR (II-III)) are involved in highly regulated processes such as cell signalling, proliferation, migration, stem cell mobilization and invasion. The aim of the current study was to analyse tumour associated factors and their effect on uPAR cleavage, and the potential implications for cell proliferation, migration and invasion. Methods: Mouse uPAR was stably overexpressed in the mouse OSCC cell line AT84. The ratio of full-length versus cleaved uPAR as analysed by Western blotting and its regulation was assessed by addition of different protease inhibitors and transforming growth factor - β1 (TGF-β1). The role of uPAR cleavage in cell proliferation and migration was analysed using real-time cell analysis and invasion was assessed using the myoma invasion model. Results: We found that when uPAR was overexpressed a proportion of the receptor was cleaved, thus the cells presented both full-length uPAR and uPAR (II-III). Cleavage was mainly performed by serine proteases and urokinase plasminogen activator (uPA) in particular. When the OSCC cells were stimulated with TGF-β1, the production of the uPA inhibitor PAI-1 was increased, resulting in a reduction of uPAR cleavage. By inhibiting cleavage of uPAR, cell migration was reduced, and by inhibiting uPA activity, invasion was reduced. We could also show that medium containing soluble uPAR (suPAR), and cleaved soluble uPAR (suPAR (II-III)), induced migration in OSCC cells with low endogenous levels of uPAR. Conclusions: These results show that soluble factors in the tumour microenvironment, such as TGF-β1, PAI-1 and uPA, can influence the ratio of full length and uPAR (II-III) and thereby potentially effect cell migration and invasion. Resolving how uPAR cleavage is controlled is therefore vital for understanding how OSCC progresses and potentially provides new targets for therapyen_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0eng
dc.subjectUrokinase plasminogen activator receptor (uPAR)eng
dc.subjectUrokinase receptoreng
dc.subjectTransforming growth factor-beta1 (TGF-β1)eng
dc.subjectPlasminogeneng
dc.subjectPlasmineng
dc.subjectCancereng
dc.subjectCell migrationeng
dc.subjectUrokinaseeng
dc.subjectInvasioneng
dc.titleCleavage of the urokinase receptor (uPAR) on oral cancer cells: Regulation by transforming growth factor - beta1 (TGF-beta1) and potential effects on migration and invasionen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2017-11-06T14:31:18Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2017 The Author(s)
dc.identifier.doihttps://doi.org/10.1186/s12885-017-3349-7
dc.identifier.cristin1483669
dc.source.journalBMC Cancer


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY